Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Circassia Builds US Respiratory Presence with AstraZeneca Deal

Executive Summary

Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.

Advertisement

Related Content

Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel